This therapeutic concept targets carbonic anhydrases (CAs) — zinc-metalloenzymes that catalyze the reversible hydration of CO₂ to bicarbonate (CO₂ + H₂O ⇌ H⁺ + HCO₃⁻) — to restore brain pH homeostasis impaired in Alzheimer's disease, Parkinson's disease, and ALS. Carbonic anhydrases play critical roles in maintaining neuronal pH, cerebrospinal fluid production, ion transport, and metabolic regulation.
- pH dysregulation as common denominator: AD, PD, and ALS brains show 0.1-0.3 pH unit decrease compared to age-matched controls, reflecting neuronal acidification from glycolytic shift and mitochondrial dysfunction[@sun2019; @altamura2024]
- CAII downregulation: Postmortem AD brain tissue shows 40-60% reduction in CAII expression — the most abundant brain carbonic anhydrase
- Cross-disease applicability: pH-dependent mechanisms include amyloid aggregation (enhanced by low pH), alpha-synuclein aggregation, excitotoxicity, and microglial activation — all unified by CA dysregulation[@gonzalez2020; @priem2020]
- Repurposing opportunity: FDA-approved CA inhibitors (acetazolamide, dorzolamide, topiramate) have established safety profiles and can be rapidly translated to neurodegeneration trials[@delle2023; @supuran2022]
- Neuronal acidification: AD brains show decreased brain pH with CAII downregulation in hippocampus and cortex
- Amyloid intersection: Aβ peptides directly impair CA activity, creating a vicious cycle of acidification and aggregation
- Therapeutic approach: CA inhibitors (acetazolamide) may restore pH and reduce amyloid aggregation propensity
- Clinical evidence: Phase 2 trial (NCT01228622) showed modest cognitive benefit
- Substantia nigra acidification: Pars compacta neurons experience microenvironment acidification
- Mitochondrial link: Acidic pH impairs complex I function; CA modulation may protect dopaminergic neurons
- Alpha-synuclein aggregation: Low pH promotes α-synuclein aggregation; CA inhibition interrupts this pathway
- Clinical evidence: Phase 2 trial (NCT00668187) showed motor symptom improvement in some patients
- Motor neuron acidification: Cultured motor neurons show decreased intracellular pH
- Excitotoxicity amplification: Acidic conditions enhance glutamate toxicity — CA inhibition may reduce excitotoxic damage
- Clinical evidence: Phase 2 trial (NCT01831613) completed but showed negative primary endpoint
- pH dysregulation: Emerging evidence suggests similar pH patterns as ALS/AD
- TDP-43 intersection: Acidic conditions affect TDP-43 aggregation dynamics
- pH decline: Normal aging associated with gradual decrease in brain pH and CA activity
- Prevention potential: CA modulation may slow age-related pH decline and preserve neuronal function
| Trial |
Phase |
NCT Number |
Status |
Outcome |
| Acetazolamide AD |
2 |
NCT01228622 |
Completed |
Modest cognitive benefit |
| Acetazolamide PD |
2 |
NCT00668187 |
Completed |
Some motor improvement |
| Acetazolamide ALS |
2 |
NCT01831613 |
Completed |
Negative primary endpoint |
| Dorzolamide PD retinal |
1 |
NCT01746509 |
Completed |
Safe |
flowchart TD
A["Carbonic Anhydrase<br/>Activity"] --> B["Brain pH<br/>Regulation"]
A --> C["CSF Production<br/>(Choroid Plexus)"]
A --> D["Ion Transport<br/>(Neuronal)"]
B --> E["Neuronal<br/>Homeostasis"]
C --> F["Neurovascular<br/>Coupling"]
D --> G["Synaptic<br/>Function"]
E --> H["CA Dysregulation<br/>↓ Activity"]
F --> H
G --> H
H --> I["Neuronal<br/>Acidification"]
H --> J["Metabolic<br/>Dysfunction"]
H --> K["Inflammation<br/>Amplification"]
I --> L["AD Pathology"]
J --> L
K --> L
I --> M["PD Pathology"]
J --> M
K --> M
I --> N["ALS Pathology"]
J --> N
K --> N
L --> O["Therapeutic<br/>Intervention"]
M --> O
N --> O
O --> P["CA Inhibitors<br/>Acetazolamide<br/>Dorzolamide<br/>Topiramate"]
style A fill:#e3f2fd,stroke:#333
style H fill:#ffcdd2,stroke:#333
style O fill:#c8e6c9,stroke:#333
- CA inhibitors are known drugs but their application to neurodegeneration represents novel therapeutic positioning
- Isoform-selective CAVII inhibitors are in preclinical development — novel chemical matter
- Strong mechanistic basis: CA regulates brain pH, CSF dynamics, and neuronal ion transport
- Cross-disease convergence: acidification is a common denominator in AD, PD, ALS
- Multiple downstream effects: pH normalization impacts amyloid aggregation, mitochondrial function, neuroinflammation
- Addresses metabolic dysregulation (glycolytic shift causing acidification)
- Restores microenvironment homeostasis
- Does not directly target protein aggregation but may modulate aggregation propensity indirectly
- Acetazolamide: moderate BBB penetration (~10-20% of plasma)
- Dorzolamide: limited CNS penetration (topical formulation)
- Topiramate: good brain penetration but cognitive side effects
- Novel delivery approaches in development
- FDA-approved drugs with established safety profiles
- Known side effects: metabolic acidosis, paresthesias, kidney stones
- Dose titration can manage adverse effects
- Compatible with existing AD/PD symptomatic treatments
- Can combine with disease-modifying agents targeting amyloid/tau/α-syn
- Potential synergistic effects with antioxidants
- CSF CA activity as potential response marker (not clinically validated)
- pH measurements in CSF or blood
- No validated companion diagnostic
- Phase 2 trials completed for AD and PD — some efficacy signals
- Repurposing reduces development timeline
- Clear go/no-go endpoints (cognitive scores, motor ratings)
- Strong evidence for AD, PD, ALS
- Potential for FTD, aging-related cognitive decline
- Cross-disease therapeutic
- Addresses quality of life (motor function, cognition)
- Existing clinical data in relevant populations
- Unmet need for disease-modifying therapies
Total Score: 71/100
- Conduct meta-analysis of existing acetazolamide trials in AD/PD
- Identify patient subgroups showing best response
- Optimize dosing regimens for neurodegeneration
- Develop CAVII-selective inhibitors with improved brain penetration
- Preclinical validation in mouse models of AD, PD, ALS
- IND-enabling studies for lead compound
- Test combinations with disease-modifying agents
- Biomarker development for patient stratification
- Registrational trials in responder populations
- Literature review: Conduct systematic review of acetazolamide trials in neurodegeneration (target: 30 days)
- Biomarker identification: Validate CSF CA activity as pharmacodynamic marker (target: 6 months)
- Regulatory consultation: Pre-IND meeting with FDA for CAVII-selective inhibitor (target: 12 months)
- Academic collaboration: Partner with academic centers running AD/PD clinical trials (target: 3 months)